Login
  • Bookmark
  • PDF
  • Share
  • CaseIQ

KLEIN-BECKER v. RUSH INDUSTRIES, INC. (D.Utah 2005)

United States District Court, D. Utah, Central Division.
Aug 16, 2005
CONSENT ORDER AND JUDGMENT RE: RUSH INDUSTRIES, INC.

PAUL CASSELL, District Judge

In accordance with the request and consent of Plaintiff Klein-Becker usa, LLC ("Plaintiff" or "Klein-Becker") and Defendant Rush Industries, Inc. ("Defendant" or "Rush"), the Court finds and Orders as follows:

1. This Court has jurisdiction over the parties, Klein-Becker usa, LLC ("Klein-Becker") and Rush Industries, Inc. ("Rush"), and the subject matter of this action, and venue is proper in this Court.

2. Klein-Becker is a limited liability company organized and existing under the laws of the State of Utah, with its principal place of business at 5742 West Harold Gatty Drive, Salt Lake City, Utah.

3. Rush is a corporation organized and existing under the laws of the State of New York with its principal place of business located at 150 Herricks Road, Mineola, New York.

4. Klein-Becker is a leader in the industry of life-enhancement products, such as nutritional and cosmetic products. Klein-Becker products enjoy a reputation in the industry as novel formulations containing high-quality ingredients.

5. Klein-Becker's products are sold through the Internet, retail outlets, and independent distributors located throughout the United States.

6. Klein-Becker's products are advertised and promoted in numerous print media of national circulation and on the Internet.

7. At all times material hereto, Klein-Becker's cosmetic products have been promoted and sold under its distinctive trademarks, of which it is the Exclusive Licensee, and trade dress.

8. Klein-Becker's extremely successful cosmetic products are marketed under the federally registered trademarks StriVectin-SD* (Striadril*) (hereinafter "StriVectin"). StriVectin is an over-the-counter, topically-applied anti-wrinkle or anti-line cream, which was originally intended for use after pregnancy to help reduce the appearance of stretch marks.

9. After it was discovered that StriVectin helped reduce the appearance of fine lines, wrinkles, and "crow's feet" around the face, consumers began purchasing and using StriVectin to improve their complexion.

10. A novel and creative advertising campaign was implemented promoting the benefits of using StriVectin for reducing the appearance of fine lines, wrinkles and "crow's feet."

11. A great deal of time, effort, and money has been expended to market, advertise and promote StriVectin.

12. A great deal of time, effort, and money has been expended to develop Klein-Becker's intellectual property rights in connection with StriVectin.

13. Klein-Becker's products have developed a reputation of high quality and goodwill in the cosmetics industry, and as a result, the consuming public has come to associate Klein-Becker with StriVectin under the aforementioned trademarks and trade dress.

14. StriVectin-SD* contains a variety of ingredients, including a proprietary complex referred to as the Striadril® complex. The Striadril® complex contains several key ingredients, including a five amino acid peptide known by its International Nomenclature of Cosmetic Ingredients name as "palmitoyl pentapeptide-3" ("PP3"). The number "3" when used in connection with the word "pentapeptide" denotes a particular five ("penta") amino acid sequence ("peptide"), known by the shorthand "Pal-KTTKS."

15. A "peptide" is a natural or synthetic compound containing two or more amino acids linked by the carboxyl group of one amino acid to the amino group of another. Thus, a pentapeptide is a compound containing five linked amino acids. PP3 is the linked compound PAL-LYS-THR-THR-LYS-SER.

16. The efficacy claims for StriVectin-SD* concerning the key ingredient PP3 are based, in part, on the results of a series of studies that were presented in July 2002, at a meeting of the 20th World Congress of Dermatology in Paris, France.

17. The studies presented concerning PP3 demonstrated that PP3 assists in improving the appearance of fine lines and wrinkles, but only when used in a minimum concentration of three ppm. The studies concerning PP3 make no claims concerning its efficacy in concentrations below three ppm.

18. Rush is a competitor of Klein-Becker that creates, manufactures, distributes, and/or designs product labeling and packaging for, inter alia, skin care products for sale through retail establishments, including the product at issue herein.

19. Rush owns and operates an interactive, fully commercial website at www.rushindustries.com.

20. After StriVectin attracted national media attention and experienced record-breaking sales, Rush began distributing and/or selling a cosmetic cream called "Palmitone," which purports to improve the appearance of a consumer's skin.

21. In the advertising and sale of Palmitone, Rush has adopted a similar trade dress to Klein-Becker's StriVectin products, which is likely to confuse the consuming public as to Palmitone's relation to Klein-Becker's products, and allows Rush to unfairly trade upon Klein-Becker's goodwill.

22. Like the trade dress for Klein-Becker's StriVectin-SD® products, the Palmitone trade dress used by Rush has substantially the same ornamental features, including:

a. A pale background with dark-colored lettering and different-colored accents;

b. The product name in the same large, black font;

c. A colored band beneath the product name in which a suggested product use is imprinted; and
d. Bullet point informational text beneath the band and over the net weight of the contents of the tube.

23. Klein-Becker's StriVectin-SD product is sold in a flexible, six-ounce squeeze-tube with a sealed end and a flat, plastic cap for dispensing the contents.

24. The Palmitone product is also sold in a flexible, six-ounce squeeze-tube with a sealed end and a flat, plastic cap for dispensing the contents.

25. The trade dress for the Palmitone product is confusingly similar to Klein-Becker's trade dress for the StriVectin-SD® products in order to make Palmitone appear as if it were part of the family of Klein-Becker products and thereby improperly profit from Klein-Becker's goodwill.

26. The StriVectin-SD® trade dress and the Palmitone trade dress are typically viewed by the consumer prior to purchase.

27. Rush is marketing the infringing product by trading off and presenting Klein-Becker's trade dress for the StriVectin-SD® products.

28. Klein-Becker has not granted Rush any right, assignment, license, or permission to use the confusingly similar trade dress, nor would Klein-Becker grant such rights.

29. Rush, in marketing Palmitone, has made a number of statements that are either literally false or materially misleading, including false and misleading comparisons between Palmitone and StriVectin-SD®, in violation of Utah and federal law.

30. Rush has advertised its Palmitone product through a series of statements touting the ability of Palmitone to fight wrinkles based on the published PP3 studies.

31. The Palmitone tube itself states that the Palmitone product "contains Pal-KTTKS," and is "Clinically Proven to Diminish Wrinkles (With Active Amino Peptides)."

32. The Palmitone tube also states:

a. "Totally Advanced-Palmitoyl-Pentapeptide (Pal-KTTKS), an effective compound that's been clinically shown to stimulate the formation of collagen and elastin."
b. "Total technology — wrinkle reduction with super firming agents that fight wrinkles and stretch marks."
c. "Palmitone helps reduce the appearance of wrinkles and stretch marks for smoother, healthy and fresh looking skin, guaranteed."

33. The ingredient deck on the back of the Palmitone tube identifies PP3 as the third of more than forty ingredients.

34. Rush's advertising also includes a series of statements touting the ability of Palmitone to fight wrinkles based on the published PP3 studies. Those statements include, without limitation:

a. "A unique breakthrough in anti-wrinkle skin treatment with Palmitoyl Pentapeptide-3, a collagen boosting protein tested and proven to reduce skin wrinkles and decrease the signs of aging without painful Botox treatments."
b. "This nutrient rich formula is blended with a powerful addition of PP-3 and POPCL peptides — amino acids proven to reduce fine lines and wrinkles."
c. "Nutrient rich formula is blended with collagen boosting protein and powerful selection of ingredients to reduce fine lines and wrinkles."

35. Moreover, Rush's advertising includes a "before and after" photograph taken from the PP3 study, as well as specific results achieved from the use of PP3 at concentrations of at least three ppm.

36. Rush's statements concerning the proven effectiveness of PP3 represent to consumers that the Palmitone product contains at least the amount of PP3 that was used in the PP3 studies actually demonstrating that PP3 has an effect on the appearance of wrinkles.

37. The Palmitone product contains less than the three percent PP3 utilized in the studies that demonstrated PP3's ability to fight the appearance of wrinkles.

38. Defendant Rush has advertised Palmitone on its fully interactive, commercial website.

39. This advertising includes the statement, "Compare it to StriVectin-SD at over $100," followed by a side-by-side comparison of the ingredients in the two products. The side-by-side comparison purports to demonstrate that Palmitone and StriVectin-SD contain exactly the same ingredients.

40. Rush's comparative statement, and its use of the side-by-side ingredient comparison, represents to consumers, or causes consumers to believe, that (1) the ingredients in Palmitone are identical to those in StriVectin-SD®, and are found in the same amounts or concentration as those in StriVectin-SD®; and that (2) the Palmitone formula has the same effect on the human body as StriVectin-SD®.

41. Rush's comparative statement, and its use of the side-by-side ingredient comparison, is confusing and has a tendency to deceive, because it represents to consumers, or causes consumers to believe, that (1) the ingredients in Palmitone are identical to those in StriVectin-SD®, and are found in the same amounts or concentration as those in StriVectin-SD®; and that (2) the Palmitone formula has the same effect on the human body as StriVectin-SD®.

42. StriVectin-SD® and Palmitone do not contain the same ingredients or the same amounts or concentration of ingredients.

43. StriVectin-SD® and Palmitone do not have the same effect on the human body.

44. Rush's comparative statement, its use of the side-by-comparison, and its choice of the Palmitone trade dress, representing (1) the ingredients in Palmitone are identical to those in StriVectin-SD®, and/or are found in the same amounts or concentration as those in StriVectin-SD®; and that (2) the Palmitone formula has been clinically proven to have the same effect on the human body as StriVectin-SD®, conveys a message that is expressly and/or impliedly false or misleading.

ORDER

Based on the stipulation of the parties, including a stipulation to the foregoing findings of fact and the following form of Order, and good cause appearing, the Court hereby makes the following Permanent Injunction and Order:

1. Rush and any and all individuals and entities under its direction or control, including, without limitation, its partners, employees, officers, directors, attorneys, agents, distributors, retailers, and any and all persons in active concert with Rush who receive actual notice of this Permanent Injunction are permanently enjoined from, and shall forever cease and desist from using, Plaintiff's, and its related entities', product names, trademarks, trade names, trade dress or any confusingly similar imitations thereof, including but not limited to the StriVectin name, mark and dress, and from making any false or misleading statements about the Palmitone product or any similar product, in any advertising and/or in any promotional activities, including but not limited to any promotional activity on the internet as well as print, magazine, radio, and television advertisements and/or promotions.

2. Defendants shall, within one (1) business day of entry of this Order, expressly request in writing that all of Rush's distributors or resellers that have received the Palmitone product immediately cease the sale of such product, to pull all such product from their shelves, and return such products to Rush. Within three (3) business days of entry of this Order, Rush shall provide Klein-Becker and its counsel with a notarized affidavit of an appropriate officer and representative of Rush memorializing compliance with this provision. A listing of the names and addresses of all such distributors or resellers contacted shall be retained by Rush. In the event Rush has no distributors or resellers of the Palmitone product, this provision will be satisfied by providing Klein-Becker and its counsel with a notarized affidavit of an appropriate officer or representative of Rush so stating.

3. Rush shall, within two (2) business days of entry of this Order, provide written notice to any and all persons and/or entities that provided or are providing any design and/or manufacturing services for Rush for the Palmitone product of the contents of this Order, and informing all such persons and or/entities that they are no longer to design and/or manufacture any items using Klein-Becker's trademarks or trade dress or any confusingly similar imitations thereof, or any false or misleading statements about the Palmitone product. Within three (3) business days of entry of this Order, Rush shall provide Klein-Becker and its counsel with a notarized affidavit of an appropriate representative of Rush memorializing compliance with this provision.

4. Rush shall, within three (3) days of entry of this Order, destroy all materials utilizing trade dress confusingly similar to Klein-Becker's trade dress for its products or false or misleading statements about Rush's products, including without limitation product labels, packaging, and advertisements, within its custody or control. Within seven (7) business days of entry of this Order, Rush shall provide Klein-Becker and its counsel with a notarized affidavit of an appropriate representative of Rush memorializing compliance with this provision. Within thirty (30), sixty (60), and ninety (90) days of the date of entry of this Order, Rush shall provide Plaintiff with a summary of all products returned by Rush's distributors and resellers, and provide a similar affidavit as set forth in paragraph 2, above, establishing compliance with this provision.

5. Rush and any related entities under Rush's direction or control shall forever cease and desist from using Klein-Becker's trademarks or trade dress or any confusingly similar imitations thereof, and from making any false or misleading statements about its products, in advertising and/or in any promotional activities within Rush's direction or control in any medium, including, without limitation, print, magazine, radio, television, and the Internet.

6. Rush shall forever cease and desist from comparing, marketing, advertising and/or promoting any products, in a manner which directly, indirectly, expressly, impliedly or otherwise compares those products' effectiveness, ingredients, results, source, origin, price, or intended use(s) to any product manufactured, marketed, distributed, or sold by Plaintiff or its related entities, including but not limited to the StriVectin-SD (Striadril) product, unless so authorized by Plaintiff or its related entities in writing.

7. Rush shall not be liable for damages so long as it remains in compliance with this Order.

8. Each party shall bear their respective costs and attorney's fees incurred in this action.

9. In any subsequent action to enforce this Order in which the Court finds by a preponderance of the evidence that a breach or violation of this Order has occurred, the prevailing party shall be awarded all of its attorney fees and costs incurred in relation to any enforcement action for breach or violation of this Order.

10. Within seven (7) business days of the date of entry of this Order, Rush shall provide a copy of this Order, certified, return-receipt first class U.S. mail to all persons and/or entities that Rush hired or retained to prepare and/or distribute advertising and/or marketing materials for the Palmitone product. Rush shall further notify the foregoing persons or entities that Rush has agreed to abide by the terms of this Order. Within fourteen (14) days following the date of entry of this Order, Rush shall provide Klein-Becker and its counsel with copies of documentation evidencing Rush's compliance with this provision. Such documentation shall consist of copies of the letters sent by Rush in accordance with this paragraph, copies of the envelopes or mailing labels used by Rush to forward the required documentation, copies of receipts received back to confirm acceptance of delivery and a notarized affidavit of an appropriate representative of Rush corroborating compliance with this provision. If applicable, within one hundred twenty days after the entry of this Order, Rush shall provide to Klein-Becker written notification that it has received all of the return-receipts or the returned letters (to the extent undeliverable or unaccepted) from the letters sent pursuant to this paragraph.

11. Providing false information pursuant to this Order shall constitute a violation thereof.

12. This Order, to the extent authorized by Fed.R.Civ.P. 65(d), shall be binding upon any persons or entities who or that receive notice of this Order. This Order shall be deemed to have been served upon the parties at the time of its execution by the Court and service on counsel for the parties. The Parties unconditionally agree to waive any and all rights of appeal they may have in connection with the entry of this Order.

13. This matter is dismissed, in its entirety, with prejudice, provided however, that this Court shall retain on-going jurisdiction, venue and authority to enforce the terms of this Order. In particular, as to the parties' rights and obligations herein, any aggrieved party may file and serve a motion to enforce this Order, after which the opposing party shall have seven (7) business days to file and serve any opposing papers, and the aggrieved or moving party shall have five (5) business days to file and serve any reply papers. Any such motion to enforce shall be heard and submitted to this Court on an expedited basis, as permitted by this Court. This Court retains the right to modify or amend the terms of this Order, including making modifications or amendments for purposes of advancing or preserving the intent and purpose thereof.